Loading stock data…
Lyell Immunopharma (LYEL)
$13.53-0.84 (-5.85%)
Market ClosedLast close Sep 8
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Lyell Immunopharma, Inc. in the Healthcare sector is trading at $13.53 with a market capitalization of $302M. Wall Street consensus targets $37.88 (8 analysts), implying a +179.9% move over the next 12 months. The stock is currently near its 52-week low of $11.47, remaining 33.3% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +179.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $4,000↑ | $2,000↓ | $6,000↓ | $15,000↑ | $8,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$47.34M↓ | -$44.26M↑ | -$61.31M↓ | -$37.25M↑ | -$45.70M |
| Net Income | -$44.76M↓ | -$24.15M↑ | -$140.72M↓ | -$38.85M↑ | -$42.68M |
Peer Comparison
JNJUNHPFE
Fundamentals
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtage...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$301.71M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-90.04%
Volume
Today's trading volume
82,389
Recent News
Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls
Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls
Here Are Thursday’s Top Wall Street Analyst Research Calls: AppLovin, Charles River, Global Payments, HubSpot, Insulet Corporation, Roper Technologies, Sabra Health Care, Western Digital, Zillow Group, and More
Wall Street analysts made some dramatic moves on Thursday, slashing price targets by double digits on several high-profile names while upgrading others to buy. Find out which stocks got the most surprising treatment before the opening bell.
Wall Street Analysts Think Lyell Immunopharma (LYEL) Could Surge 176.02%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 176% in Lyell Immunopharma (LYEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is Lyell Immunopharma (NASDAQ:LYEL) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Lyell Immunopharma's Cancer Therapy Shows Improved Safety in Phase 1 Study
Lyell Immunopharma (LYEL) said Monday that its investigational CAR-T therapy, LYL273, showed improve